Deucrictibant XR: CHAPTER-3 results and prophylaxis evidence
Clinical evidence review based on public sources. Unpublished results and unavailable details are identified; this is not the sponsor’s full clinical study report.
Bradykinin receptor blockade
Deucrictibant antagonizes the bradykinin B2 receptor, targeting the effector pathway causing vascular leakage in bradykinin-mediated angioedema. Prophylaxis requires sustained protection before an attack occurs; acute relief and prevention are separate clinical claims even when the molecule is the same. [1] [2]
Interpretation: blocking a final common pathway offers a rationale across HAE subtypes, but heterogeneity remains. Normal-C1-inhibitor HAE is not interchangeable with classic C1-inhibitor deficiency, and a very small subgroup cannot establish equal efficacy across genetic or diagnostic categories. Clinical attacks rather than a laboratory biomarker are the essential outcome because the intended benefit is fewer episodes that interrupt breathing, activity and daily life.
Immediate release to extended release
CHAPTER-1 used immediate-release capsules twice daily, including 20 mg twice daily for 40 mg/day. CHAPTER-3 tested the intended commercial XR tablet at 40 mg once daily for 24 weeks. The formulation bridge is a clinical question, not merely a change in packaging. [1] [3] [4]
Interpretation: adequate trough receptor antagonism should protect the interval between doses, while a high peak alone may leave a vulnerable period. The pivotal result tests the whole dosing regimen, including adherence, rather than validating a particular plasma threshold. On-demand IR regulatory review should not be confused with prophylactic XR approval: exposure schedules, endpoints and supporting datasets differ. The August update placed the IR FDA action date in April 2027, while XR prophylaxis filing was subsequently planned for 2027.
CHAPTER-1 randomized proof of concept
CHAPTER-1 randomized 34 patients to placebo, 20 mg/day or 40 mg/day for 12 weeks. At 40 mg/day the monthly attack-rate reduction versus placebo was 84.5%, with 95% CI 53.8–94.8 in the publication. The arm sizes were 11, 11 and 12 respectively. [2] [3] [5]
Interpretation: this large effect had substantial uncertainty because of the small sample and variable recurrent attacks. Two high-dose participants with less than four weeks' exposure were excluded from certain threshold-response summaries, which must not be mistaken for an all-randomized responder analysis. The open-label extension adds duration but loses the randomized comparator; comparing extension rates with original baseline exaggerates causal certainty if treatment selection and retention are ignored.
| Study / measure | Result | Interpretation |
|---|---|---|
| CHAPTER-1 40 mg/day | 84.5% attack-rate reduction / 发作率下降 | 95% CI 53.8–94.8; n=12 |
| CHAPTER-3 overall / 总体 | 83% reduction; p<0.0001 | 55 active / 治疗; 30 placebo / 安慰剂 |
| CHAPTER-3 HAE-1/2 subset | 87% reduction / 下降 | 80 participants / 人 |
CHAPTER-3 already reported
On September 8, 2026, Pharvaris reported positive CHAPTER-3 results. Eighty-five participants from 21 countries were randomized 2:1: 55 to XR and 30 to placebo. The overall monthly attack-rate reduction was 83% (p<0.0001); secondary efficacy endpoints passed a sequential multiplicity procedure. This catalyst is completed, not awaiting an H2 readout. [1]
The release reported 87% reduction in the 80 patients with HAE types 1 or 2. Only five participants therefore lay outside that subgroup; this arithmetic describes sample composition, not a subgroup-specific response. The overall and subset estimates overlap and must not be treated as independent replications. Absolute monthly rates, confidence intervals and patient-level attack-free distributions should accompany the headline as the full dataset becomes available.
Recurrent-event interpretation
Clinical interpretation: an 83% relative attack-rate reduction does not mean 83% of patients were attack-free. A recurrent-event model can assign considerable influence to patients with frequent attacks, making both the modeled average and patient-level distribution useful. The same principle applies to reductions in moderate/severe attacks and use of rescue medication. [1] [2]
The blinded 24-week period establishes comparative prevention under the trial's ascertainment rules. Longer observation is needed for persistence, adherence and rare attacks involving the airway. Baseline attack burden, confirmation rules, omitted diary days and changes in background prophylaxis should be visible in the final publication. Statistical significance across a controlled hierarchy is stronger than isolated nominal secondary p values, but still does not establish comparative effectiveness against injectable prophylaxis because no injectable active arm was randomized.
An attack-free interval also needs its stated duration: freedom for the last month is not the same endpoint as freedom for the full randomized period. Both can be useful, but their percentages cannot be exchanged without changing the clinical claim.
Safety and development responsibilities
The CHAPTER-3 topline described predominantly mild or moderate TEAEs and no treatment-related serious AEs. Complete arm-level severe-event and discontinuation tables were not supplied in the extracted text. Lack of those tables must not be translated into zero all-cause serious events. [1] [4]
Interpretation: long-term receptor blockade should be judged with cardiovascular observations, hepatic tests and sustained exposure, not only an overall tolerability adjective. CHAPTER-4 can increase exposure duration but cannot recreate the placebo comparison. Pharvaris reported €318 million cash at June 2026; funding supports execution of extensions and submission work, while approval still requires review of the complete benefit–risk and manufacturing package.
Sources / References
For general information and research only; not investment or medical advice. Coverage and disclosed data may be incomplete. Verify primary sources before making decisions.